FDA’s top gene therapy regulator is leaving his role
Vijay Kumar, the FDA's lead official for cell and gene therapy, is stepping down after one year in the role.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
The acting director of the FDA’s cell and gene therapy division, Vijay Kumar, is departing from his leadership position. The move comes exactly one year after he assumed the role at the agency.
Coverage from BioSpace, Endpoints News, BioPharma Dive, Fierce Biotech, and STAT News confirms the leadership change. These outlets focus on the timing of his resignation and his specific oversight of the gene and cell therapy portfolio.
It remains to be seen who will be appointed to fill the vacancy created by his departure. Details regarding a permanent replacement or an interim successor have not been specified.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated just now.
Quick answers
Who is leaving the FDA?
Vijay Kumar, the acting director of cell and gene therapies, is leaving his position.
How long was the regulator in his role?
He served in the role for one year.
Has a successor been named?
Coverage does not yet specify who will replace him.
Coverage (6)
- Top FDA gene and cell therapy regulator to step down Yahoo · 20h ago
- FDA’s cell and gene therapy head steps down after 1 year BioSpace · 20h ago
- FDA’s acting director of cell and gene therapies to leave position Endpoints News · 20h ago
- Top FDA gene and cell therapy regulator to step down BioPharma Dive · 20h ago
- FDA gene therapy regulator Vijay Kumar steps down from leadership role Fierce Biotech · 20h ago
- FDA’s top gene therapy regulator is leaving his role statnews.com · 20h ago
Topics
Related trends
Exclusive: FDA allows ZYN to sell pouches on health benefits
FDA greenlights Philip Morris to market ZYN nicotine pouches as a less harmful alternative to cigarettes
FDA panel on peptides will include experts who promote the unproven chemicals favored by RFK Jr.
FDA’s peptide advisory panel sparks controversy over ties to RFK Jr.-backed unproven treatments
French biotech stock soars 34% after new data on experimental medicine
Shares of the French biotechnology company Abivax have surged following the release of new clinical data regarding its experimental drug, obefazimod.
What Comcast-NBC Universal Split Faces In D.C.’s Trump-Influenced Regulatory Road
Comcast is spinning off NBCUniversal and Sky from its cable operations, prompting questions about regulatory hurdles and future media industry consolidation.
FDA Selects Seven Participants for PreCheck Pilot Program to Advance U.S. Drug Manufacturing
FDA’s PreCheck pilot program accelerates U.S. drug manufacturing—here’s who’s leading the charge
Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities
The FDA has selected Eli Lilly and Regeneron for a pilot program designed to accelerate the review process for new pharmaceutical manufacturing facilities.